{"id":"NCT01599650","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion","officialTitle":"A 24-month, Phase IIIb, Open-label, Randomized, Active Controlled, 3-arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization-criteria-driven PRN Dosing Regimen With 0.5-mg Ranibizumab Intravitreal Injections Applied as Monotherapy or With Adjunctive Laser Photocoagulation in Comparison to Laser Photocoagulation in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2012-05-16","resultsPosted":"2016-11-10","lastUpdate":"2016-11-10"},"enrollment":455,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Branch Retinal Vein Occlusion"],"interventions":[{"type":"DRUG","name":"Ranibizumab","otherNames":["Lucentis"]},{"type":"PROCEDURE","name":"Laser","otherNames":[]}],"arms":[{"label":"1-ranibizumab monotherapy","type":"EXPERIMENTAL"},{"label":"2-ranibizumab with laser","type":"EXPERIMENTAL"},{"label":"3-laser monotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing administered with or without adjunctive laser treatment versus laser photocoagulation (the current standard of care) up to Month 6 in patients with visual impairment due to ME secondary to BRVO. Additionally the results of this study will provide long-term (24-month) safety and efficacy data for ranibizumab, administered with or without adjunctive laser treatment in this indication.","primaryOutcome":{"measure":"Mean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO)","timeFrame":"Baseline, 6 Months","effectByArm":[{"arm":"1-ranibizumab Monotherapy","deltaMin":59.5,"sd":11.78},{"arm":"2-ranibizumab With Laser","deltaMin":56.6,"sd":13.19},{"arm":"3-laser Monotherapy","deltaMin":56.8,"sd":13.86}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":82,"countries":["Australia","Canada","Czechia","Denmark","France","Greece","Hungary","Ireland","Italy","Netherlands","Poland","Portugal","Slovakia","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["34934034","28807635","27039022"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":180},"commonTop":["Hypertension","Eye pain (Study eye)","Nasopharyngitis","Intraocular pressure increased (Study eye)","Conjunctival haemorrhage (Study eye)"]}}